SAB

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

Retrieved on: 
Wednesday, March 6, 2024
Senior, Research, SAB, Lecanemab, Clinical Chemistry (journal), Neuroimaging, Lund University, University, Associate, Henrik, Key, School, OGA, Principal, Research and development, Queen Silvia of Sweden, Young, Brain, Therapy, Pharmacology, SAN, UCL, Geriatric psychiatry, Eric, Biomarker, Yale School of Medicine, ACTC, Sahlgrenska University Hospital, University College London, Division, Neurochemistry, FDA, Public health, Phase II, Neurology, Senior advisor, Executive Committee, Patient, Cognition, Yale school, European Grand Prix, Biogen, Pharmaceutical industry

LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).

Key Points: 
  • LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).
  • Asceneuron is advancing development of its lead asset ASN51 into Phase II clinical development targeting Alzheimer's disease.
  • The Scientific Advisory Board members have vast experience in clinical trial design and biomarkers and will help support this promising program through Phase II clinical development.
  • I am honored to have these stellar neurodegenerative experts join our SAB at a fundamental time of development.

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

Retrieved on: 
Wednesday, March 6, 2024
Senior, Research, SAB, Lecanemab, Clinical Chemistry (journal), Neuroimaging, Lund University, University, Associate, Henrik, Key, School, OGA, Principal, Research and development, Queen Silvia of Sweden, Young, Brain, Therapy, Pharmacology, SAN, UCL, Geriatric psychiatry, Eric, Biomarker, Yale School of Medicine, ACTC, Sahlgrenska University Hospital, University College London, Division, Neurochemistry, FDA, Public health, Phase II, Neurology, Senior advisor, Executive Committee, Patient, Cognition, Yale school, European Grand Prix, Biogen, Pharmaceutical industry

LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).

Key Points: 
  • LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).
  • Asceneuron is advancing development of its lead asset ASN51 into Phase II clinical development targeting Alzheimer's disease.
  • The Scientific Advisory Board members have vast experience in clinical trial design and biomarkers and will help support this promising program through Phase II clinical development.
  • I am honored to have these stellar neurodegenerative experts join our SAB at a fundamental time of development.

New Chair and Executive Committee Members Appointed of Lymphoma Research Foundation Mantle Cell Lymphoma Consortium

Retrieved on: 
Thursday, February 15, 2024
University, SAB, Haematopoietic system, Ohio State University, LRF, Clinical professor, Health, Associate, Diagnosis, McGill University, City, Mantle cell lymphoma, MCL, Tampa General Hospital, Weill Cornell Medicine, MCLC, Internal medicine, Clinical trial, Research, Faculty, Division, MD, NHL, Cancer Institute, Cell, Executive Committee, Society, Mayo Clinic, Non-Hodgkin lymphoma, Disease, Rush University, Pharmaceutical industry

NEW YORK, Feb. 15, 2024 /PRNewswire-PRWeb/ -- The Lymphoma Research Foundation (LRF) – the nation's largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives, and patient services – is pleased to announce Tycel Phillips, MD of City of Hope and Kami Maddocks, MD of Ohio State University to the Executive Committee members and Peter Martin, MD of Weill Cornell Medicine as Chair of its Mantle Cell Lymphoma Consortium (MCLC) Executive Committee.

Key Points: 
  • "LRF's Mantle Cell Lymphoma Consortium provides a unique forum for the world's leading MCL researchers to share scientific and clinical findings, exchange ideas, and plan new collaborations," said Meghan Gutierrez, CEO of the Lymphoma Research Foundation
    The Mantle Cell Lymphoma Consortium Executive Committee helps to guide the MCLC by identifying gaps in research and patient care for this historically understudied patient population.
  • Since its inception the Mantle Cell Lymphoma Consortium brings together leading international experts to discuss the latest research findings, foster collaboration within the mantel cell lymphoma (MCL) research community, create new directions for research, and ultimately improve diagnosis and treatment for this disease.
  • "The Lymphoma Research Foundation's Mantle Cell Lymphoma Consortium provides a unique forum for the world's leading MCL researchers to share scientific and clinical findings, exchange ideas, and plan new collaborations," said Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation.
  • "I'm honored to lead this vital consortium dedicated to improving outcomes for all those impacted by mantle cell lymphoma," said Dr. Martin.

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

Retrieved on: 
Tuesday, February 13, 2024
Neoplasm, Head and neck cancer, Cetuximab, Toxicity, Doctor of Philosophy, Research fellow, Immunotherapy, SAB, University, Health, Associate, HNC, Neck, Assistant, Escape Room, SCCHN, Moores Cancer Center, Associate professor, Focus group, Oncology, Immunity, Metastasis, Biomarker, Science, Tumor microenvironment, Communication, Division, Drug resistance, MD, Lead, Patient, Publication, Cancer, Pharmaceutical industry

REHOVOT, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) --  Purple Biotech Ltd.("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced it convened a Scientific Advisory Board (SAB) focusing the discussions on NT219’s indication in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).

Key Points: 
  • “Their recognition of the critical unmet need in recurrent and metastatic head and neck cancer provides further support and momentum to our development program.
  • Now that we have determined the recommended Phase 2 dose, we are prepared to move to our next phase of development.
  • We look forward to the head and neck cancer SAB’s continued guidance and support.”
    Head & Neck Cancer SAB Members Include:
    Douglas Adkins, MD – Dr. Adkins is a Professor of Medicine and Director, Head and Neck and Thyroid Medical Oncology, at the Siteman Cancer Center, Washington University School of Medicine.
  • He is a nationally recognized expert in head and neck cancer known for his commitment to advancing patient care through clinical research.

Saudi Sports for All Federation Welcomes More Than 20,000 Participants for 2024 Riyadh Marathon

Retrieved on: 
Sunday, February 11, 2024
Women, Sports, Consumer, Men, Running, CALO, Woman, Ministry, Multimedia, GSK, Riyadh Marathon, SAB, Hisamitsu, Female, Sport, SFA, Male, PepsiCo, JPMorgan Chase, Interior design

View the full release here: https://www.businesswire.com/news/home/20240211783273/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240211783273/en/
    Riyadh Marathon Presented by SAB (Graphic: AETOSWire)
    For the first time, the start and finish line, and the accompanying Marathon Village, were located next to Kingdom Arena and Boulevard World.
  • From there, competitors of all ages and abilities could enjoy one of four races – the full marathon (42.2km), half marathon (21.1km), 10km, and 4km family run.
  • Across the four races, there were more than 20,000 participants, with a significant increase in female runners, exceeding 7,200.
  • The event was also sponsored by JPMorgan, Hisamitsu, Activia, L’Oréal, GSK, CALO, Kudu, Delta Sports, and MDLBeast.

Solas Energy Celebrates EDP Renewables North America's Successful Completion of 297 MW Wind Farm in Alberta, Canada, Paving the Way for a Sustainable Future

Retrieved on: 
Thursday, February 8, 2024
AB, Energy, EDP Renewables North America, Growth, EDP Renováveis, SAB, Restaurant, School, EDPR, Environment, Special Areas Board, TC Energy, Wind, Ministry of Energy (Alberta), Eastern United States, Radius, Renewable energy

CALGARY, AB, Feb. 8, 2024 /PRNewswire-PRWeb/ -- Solas Energy, a leader in providing comprehensive strategy and consulting services for renewable energy solutions, proudly acknowledges the operational commencement of the Sharp Hills Wind Farm in Alberta, Canada, a groundbreaking achievement by EDP Renewables North America (EDPR NA). This project, boasting 297 megawatts (MW) of installed capacity, further solidifies EDPR NA's position as a top renewable energy developer and operator in Canada.

Key Points: 
  • This project, boasting 297 megawatts (MW) of installed capacity, further solidifies EDPR NA's position as a top renewable energy developer and operator in Canada.
  • Calgary-based TC Energy, a leading energy infrastructure company, serves as the energy offtaker for the project, underlining the collaborative efforts within the industry.
  • We look forward to continued collaboration with Solas Energy focused on creating a more resilient Canadian energy grid."
  • Solas Energy remains committed to advancing the renewable energy landscape and supporting projects that contribute to the growth of sustainable energy practices.

PRODIGY BIOTECH ENTERS INTO A PARTNERSHIP AGREEMENT WITH LEADING CANCER CENTER TO ADVANCE PRODUCTS TO IMPROVE OUTCOMES IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Retrieved on: 
Tuesday, February 6, 2024
MSK, Partnership, Mortality, Alcoholic hepatitis, Research, MD, Therapy, Disease, Patient, IND, Graft-versus-host disease, Alcoholic liver disease, Immunoglobulin Y, Assistant, Drug development, Doctor of Philosophy, SAB, Dysbiosis, Gastrointestinal tract, Bloodstream infections, Cancer, Pharmaceutical industry

The accelerator program launch was announced at the MSK Life Sciences Innovation Summit in New York City on January 26, 2024.

Key Points: 
  • The accelerator program launch was announced at the MSK Life Sciences Innovation Summit in New York City on January 26, 2024.
  • Prodigy and Memorial Sloan Kettering Cancer Center (MSK) will co-develop a product targeting Enterococcus sp.
  • to treat microbial dysbiosis in patients undergoing allogenic hematopoietic stem cell transplantation.
  • February 6, 2024 – Prodigy and MSK have entered into a sponsored research agreement through the MSK Therapeutics Accelerator program to evaluate Prodigy’s product candidate for the improvement of outcomes in patients undergoing allogenic hematopoietic stem cell transplantation (allo-HCT).

SAB Biotherapeutics Announces Executive Leadership Change

Retrieved on: 
Friday, February 2, 2024
University, All, Master, Immunotherapy, Research, Therapy, Master of Science, Latin honors, T1D, Clark University, Executive, Acquisition, Sale, SAB, Small RNA, Biology, Management

SIOUX FALLS, S.D., Feb. 02, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced Samuel J. Reich, currently the Executive Chairman of SAB, will expand his role to include that of Chief Executive Officer of SAB, effective February 2, 2024.

Key Points: 
  • SIOUX FALLS, S.D., Feb. 02, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced Samuel J. Reich, currently the Executive Chairman of SAB, will expand his role to include that of Chief Executive Officer of SAB, effective February 2, 2024.
  • Eddie J. Sullivan, Ph.D., Co-Founder of SAB, will continue his role as President, and as a member of the Board of Directors (the “Board”).
  • He will report to the Board and maintain leadership of operational, research, and development functions of the Company.
  • He also founded Acuity Pharmaceuticals, Inc. in 2002, where he served as Executive Vice President until its acquisition by Opko Health, Inc., thereafter serving as Executive Vice President.

NewSpace India and SAB Launch Services sign Launch Services Agreement to fly cubesat on PSLV mission

Retrieved on: 
Tuesday, January 30, 2024
VEGA, Partnership, Orbit, NewSpace India Limited, SSLV, PSLV, NSIL, SAB, ISRO, Management

BENEVENTO, Italy, Jan. 30, 2024 (GLOBE NEWSWIRE) -- NewSpace India Limited (NSIL), the commercial arm of ISRO providing Launch Services on-board ISRO’s launch vehicles, and SAB Launch Services (SAB-LS), specialized in Launch Services for small satellites, signed at the end of 2023 a Launch Service Agreement for deploying smallsat in orbit.

Key Points: 
  • BENEVENTO, Italy, Jan. 30, 2024 (GLOBE NEWSWIRE) -- NewSpace India Limited (NSIL), the commercial arm of ISRO providing Launch Services on-board ISRO’s launch vehicles, and SAB Launch Services (SAB-LS), specialized in Launch Services for small satellites, signed at the end of 2023 a Launch Service Agreement for deploying smallsat in orbit.
  • This agreement represents a significant milestone in providing advanced and seamless solutions for small satellites complementing with PSLV and SSLV missions, the launcher portfolio with focus on commercial customers.
  • Mr. Radkakrishnan D, Chairman and Managing Director of NSIL, expressed enthusiasm about the partnership, "Our strategic collaboration with SAB empowers us to better serve the global small satellite community, also in light of our new small launch vehicle SSLV."
  • SAB-LS’s CEO, Marco Mariani, added, "This partnership is a testament to the dedication we've poured into improving our services offer.

Vintage Investment Partners Announces Two New Members of Its Strategic Advisory Board

Retrieved on: 
Tuesday, January 30, 2024
Entrepreneurship, Senior, Presidency of Barack Obama, GBS, National Council, Former, Hadassah Medical Center, Research, Ovarian cancer, Hebrew University of Jerusalem, Bank, Genius, CFA, Bank of Israel, University, LLB, Fidelity, Central Waqf Council, Economics, PGD, P&G, Education, Strauss Group, MIT, Berkshire Partners, Analysis Group, SAB, Bank Leumi, GMO, CDPQ, Finance, Harvard University, Doctor of Philosophy, First Nations in Manitoba, Cincinnati metropolitan area, Defense, IBM Consulting, Bed Bath & Beyond, Teaching, Management

Dr. Haj-Yehia served between 2019-2023 as Executive Group Chairman of Bank Leumi, the largest and oldest bank in Israel.

Key Points: 
  • Dr. Haj-Yehia served between 2019-2023 as Executive Group Chairman of Bank Leumi, the largest and oldest bank in Israel.
  • "I am thrilled to have Samer and Andy join our Strategic Advisory Board.
  • More importantly, both bring unique experience and perspectives to Vintage that we are thrilled to tap", said Alan Feld, Founder and Co-Managing Partner of Vintage.
  • The other members of the Vintage SAB include: Bradley Bloom, Former Chairman and Co-Founder of Berkshire Partners, Mark Dubowitz, CEO, Foundation for the Defense of Democracies, Ambassador S. Fitzgerald Haney, Former U.S.